knowledge -WSS

knowledge

author：comprehensive 2025-10-01 10:37:39 - browse：41168

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Fatty liver disease was alleviated by Lilly’s ‘triple

WSS

Chan Zuckerberg Biohub Chicago to focus on inflammation

A virus, fished out of a lake, may have saved a man’s life

Chemotherapy drug shortage eases slightly but still widespread

Dexcom's push to bring CGM to type 2 diabetes patients

FDA panel signals lack of confidence in Amgen cancer drug data

Hubble vs. James Webb telescope images: See the difference

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Malaria cases in Florida and Texas: Here’s what you need to know

The wait for US passports is creating travel purgatory and snarling summer plans

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT wants to know your pick for a great summer read or listen

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why age limits for politicians are a terrible idea

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Sana to lay off nearly a third of staff, de

Medical leaders decry Supreme Court decision on affirmative action

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

focus

FDA panel signals lack of confidence in Amgen cancer drug data

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Fatty liver disease was alleviated by Lilly’s ‘triple

Beware reading your test results before your doctor does

How Robert F. Kennedy Jr. distorted vaccine science

Canadians with cystic fibrosis outlive Americans by a decade

leisure time

hotspot

hotspot

focus